Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:20:50 EDT Sat 18 May 2024
Enter Symbol
or Name
USA
CA



News for U:VTRS from 2023-05-18 to 2024-05-17 - 41 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-09 06:59U:VTRSNews ReleaseViatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges
2024-05-02 17:00U:VTRSNews ReleaseViatris to Participate in the BofA Securities 2024 Health Care Conference
2024-05-01 18:31U:VTRSNews ReleaseViatris Expands Its Wellbeing Program With the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health
2024-05-01 06:59U:VTRSNews ReleaseViatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health
2024-04-16 16:30U:VTRSNews ReleaseViatris to Report First Quarter 2024 Financial Results on May 9, 2024
2024-04-15 08:00U:VTRSNews ReleaseViatris Appoints Corinne Le Goff as Chief Commercial Officer
2024-04-15 06:59U:VTRSNews ReleaseViatris Announces Launch of First Bioequivalent Generic Version of Copaxone(TM) 20 mg/mL Once-Daily in Canada
2024-04-01 07:15U:VTRSNews ReleaseOcuphire Announces the U.S. Commercial Launch of RYZUMVl(TM) (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
2024-04-01 06:59U:VTRSNews ReleaseViatris Announces the Launch of RYZUMVl(TM) (Phentolamine Ophthalmic Solution) 0.75% in the United States
2024-03-27 06:59U:VTRSNews ReleaseViatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline
2024-02-28 06:30U:VTRSNews ReleaseViatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
2024-02-28 01:00U:VTRSNews ReleaseViatris and Idorsia Enter Into Significant Global Research and Development Collaboration
2024-02-05 06:59U:VTRSNews ReleaseViatris to Announce Fourth Quarter and Full-Year 2023 Financial Results
2023-12-21 16:05U:VTRSNews ReleaseViatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference
2023-12-15 16:45U:VTRSNews ReleaseViatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer
2023-12-15 16:05U:VTRSNews ReleaseViatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders
2023-11-22 08:13U:VTRSNews ReleaseViatris Partners With Comfort Cases to Support Youth in U.S. Foster Care
2023-11-14 08:00U:VTRSNews ReleaseViatris to Participate in the Jefferies London Healthcare Conference
2023-11-13 08:00U:VTRSNews ReleaseViatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI ‚ ® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
2023-11-13 08:00U:VTRSNews ReleaseViatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI ‚ ® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
2023-11-07 16:02U:VTRSNews ReleaseViatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1]
2023-10-30 09:00U:VTRSNews ReleaseViatris to Host Webinar: The Power of Partnership to Address Antimicrobial Resistance
2023-10-25 16:01U:VTRSNews ReleaseViatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row
2023-10-23 09:00U:VTRSNews ReleaseViatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row
2023-10-20 17:00U:VTRSNews ReleaseRajiv Malik to Retire as President of Viatris Effective April 1, 2024
2023-10-18 08:00U:VTRSNews ReleaseViatris Named to 3BL's 100 Best Corporate Citizens of 2023 Ranking
2023-10-10 09:29U:VTRSNews ReleaseViatris to Release Third Quarter 2023 Financial Results on November 7, 2023
2023-10-01 17:00U:VTRSNews ReleaseViatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA
2023-09-27 08:00U:VTRSNews ReleaseViatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl ¢ „ ¢ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g.
2023-09-12 18:08U:VTRSNews ReleaseViatris Named to TIME's World ¢ € ™s Best Companies 2023 List
2023-09-12 16:35U:VTRSNews ReleaseViatris Named to TIME's World ¢ € ™s Best Companies 2023 List
2023-09-12 16:03U:VTRSNews ReleaseViatris Named to TIME's World ¢ € ™s Best Companies 2023 List
2023-09-12 14:45U:VTRSNews ReleaseViatris Named to TIME's World's Best Companies 2023 List
2023-09-05 05:00U:VTRSNews ReleaseViatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV
2023-08-07 06:59U:VTRSNews ReleaseViatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]
2023-08-07 06:54U:VTRSNews ReleaseViatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis
2023-07-31 06:59U:VTRSNews ReleaseViatris Announces Launch of Breyna ¢ „ ¢ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort ‚ ® for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kinde
2023-06-28 11:45U:VTRSNews ReleaseViatris to Report Second Quarter 2023 Financial Results on August 7, 2023
2023-05-30 09:00U:VTRSNews ReleaseViatris Named to USA Today's Inaugural List of America's Climate Leaders 2023
2023-05-22 07:40U:VTRSNews ReleaseRobert J. Coury to Transition from Executive Chairman of Viatris to Chairman Emeritus and Senior Strategic Advisor to the Board and Management at the End of the Year
2023-05-22 06:30U:VTRSNews ReleaseViatris Announces Appointment of Leo Groothuis to Company's Board of Directors